Neil Woodford’s Latest Buys And Sells: Mega-Million-Pound Calls On British American Tobacco plc, Rolls-Royce Holding PLC and Reynolds American, Inc

G A Chester examines Woodford’s buy and sell decisions on British American Tobacco plc (LON:BATS), Rolls-Royce Holding PLC (LON:RR) and Reynolds American, Inc. (NYSE:RAI).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s always useful to see which shares the experts are buying and selling — and Neil Woodford is as expert as they come.

Through his Invesco Perpetual Income and High Income funds, Woodford looks after £25 billion of client money. His Income fund has generated a superb 210% return over the last 10 years, compared with an average 124% return by his peers.

The latest half-year report for the Income fund has just been published, and there’s an added piquancy, because the trades Woodford reports preceded an announcement on 15 October that he would be leaving Invesco next April.

Not kicking the habit

Woodford has a longstanding love affair with the tobacco sector. Indeed, backing this industry when it was out of favour has proven to be one of Woodford’s best calls.

During the 1990s, many commentators were confidently predicting litigation would be the death knell for tobacco companies. This year, the obituary writers are out again, mourning an impending death from plain packaging, education and declining sales volumes.

Meanwhile, Woodford has been increasing his net exposure to tobacco, while also rotating his favoured stocks within the sector.

Woodford reduced his holding in Reynolds American (NYSE: RAI.US) by 13%, netting proceeds of £77m. My calculations suggest he sold at between $49 and $50 a share — depending on the exchange rate at the time — when the owner of such iconic brands as Camel and Pall Mall was trading on an historic price-to-earnings (P/E) ratio of around 18.

Meanwhile Woodford spent £78m on increasing his shareholding in British American Tobacco (LSE: BATS) (NYSE: BTI.US) by 16%, and a further £59m on upping his stake in Imperial Tobacco by 13%.

My sums say Woodford paid 3,511p a pop for his British American Tobacco shares (at an historic P/E of less than 17) and 2,262p a share in the case of Imperial Tobacco (at an historic P/E of less than 12).

At the time of writing, you can buy British American Tobacco at 3,206p (9% less than Woodford paid), while Imperial Tobacco’s shares have risen 2% to 2,300p.

Taking some profit on high fliers

Woodford’s biggest FTSE 100 sell during the period was Rolls-Royce (LSE: RR) (NASDAQOTH: RYCEY.US), a company whose shares have more than quadrupled since their bear-market low of 2009.

The sale netted Woodford proceeds of £23m, but was a relatively small 5% ‘top-slice’ of his holding. According to my calculations, he sold at 1,246p a share, with the historic P/E standing at a heady 21, and the dividend yield at 1.6%. Rolls-Royce’s shares are currently trading 4% lower at 1,200p.

Woodford’s second largest British blue-chip sell — raising £20m — was Reckitt Benckiser. The consumer goods group, which owns brands such as Cillit Bang and Air Wick, saw its shares rise strongly through the first half of the year.

Again, Woodford’s sale represented a relatively small top-slice (4% of the holding). My sums say he sold at 4,837p a share, with the historic P/E at 18. Reckitt Benckiser’s shares are currently trading a tad lower at 4,816p.

Buying 40% of a company

There wasn’t too much change in Woodford’s net exposure to healthcare — another of his favourite industries — and AstraZeneca and GlaxoSmithKline remain the fund’s top two holdings.

However, Woodford did buy a whopping 40% of a smaller company in the sector! In an interesting move, he participated in a £30m initial public offering (IPO) for AIM-market debutante NetScientific. The company, which is chaired by pharma industry veteran Sir Richard Sykes, a former chairman of GlaxoSmithKline, commercialises late-stage research from US and UK universities.

The companies in NetScientific’s portfolio include, WANDA, which has designed a wireless digital health system for the remote management of chronic diseases, and Vortex BioSciences, which is developing a novel technology for blood-based cancer diagnosis and monitoring.

Woodford bought NetScientific shares at 160p in the IPO; today, they’re trading at 135p.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »